Dishman Carbogen Amcis Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/gj740t585wae4c0fm8y37t6u.pdf

Key Takeaways


Q1 Performance: The Deferred Order

Harshil Dalal: "If you're talking about CHF1 crore of revenue, this could translate close to70% addition to the EBITDA. That's how the mechanics work. The more we are able to work on the top line, the more it will translate straight away into the EBITDA."

India Entity Ramp-Up & Tech Transfers


Commercial & Pipeline Progress

Harshil Dalal: "I think we would have to wait for the customer's feedback on what do the forecast for the next12 months,24 months going into the future. Because initially, everybody thinks it's a blockbuster drug, but we'll just have to see."

Commercial Leadership & Go-To-Market

Angela Ameriks: "First and foremost, it's undeniable that we strive for more business. We need to increase our prospecting efforts and work closely with the opportunities that we have to ensure that they close."

Balance Sheet & Promoter Fundraise


Guidance & Commitments

CommitmentSpecificsTimeline
FY27 group revenue growthSingle-digit growthFY27[20–21]
FY27 group EBITDA marginSimilar to FY26, maybe a little bit higherFY27
Indian entity FY27 revenue growthAt least30–35% vs previous yearFY27
Indian entity FY27 operating marginClose to about10%FY27
Promoter fundraise closureRaise funds in foreign currency, infuse as ECBNext 60–90 days
FY28–29 group revenue growthMore than10% YoYFY28–29
FY28–29 group EBITDA marginCloser to25–26% (pre-EDQM-issue levels)FY28–29
French entity and India operations growthAt least double-digit growthFY28–29
First tech transfer (Switzerland to Bavla)Activity started, to be completedWithin FY27
Japanese co-investmentOperationalCourse of next calendar year

Key Metrics

MetricQ1 FY27
Revenue from operations₹677.6 cr, 4% YoY de-growth from ₹708 cr in Q1 FY26
EBITDA₹60 cr, compared to ₹140.6 cr in Q1 FY26
Loss before tax₹51.2 cr
Tax expense₹6.6 cr
Finance cost~₹37 cr, reduced vs previous quarter
Foreign exchange impact₹11.73 cr loss, mainly from USD/CHF fluctuation
CDMO segment revenue₹534.3 cr, compared to ₹611.2 cr in Q1 FY26
CDMO segment EBITDA margin6.3%, compared to 17.9% in Q1 FY26
Marketable Molecules segment revenue₹143.2 cr, significant growth from ₹96.8 cr in Q1 FY26
Marketable Molecules segment margin₹1.86 cr, normalized from 32% margin in Q1 FY26 on high analogue sales
ADC revenue~₹150 cr, including linker, payload, and hyper molecule
CapExCHF 0.49 cr
Net debt (excluding lease liabilities)CHF 15.36 cr as of 30 June 2026
FY27 revenue growth guidanceSingle-digit growth
FY27 EBITDA margin guidanceSimilar to last year, maybe a little higher
FY28-29 revenue growth expectationMore than 10% YoY
FY28-29 EBITDA margin expectationCloser to 25-26%
Indian entity FY27 revenue growth guidanceAt least 30-35% YoY
Indian entity FY27 operating margin guidanceClose to about 10%
Phase III molecules commercialized in Q1Zero
Late-phase molecules promoted to Phase IIIThree, from Phase I/II
Programs under development700-800 across all phases
Promoter fundraise approvalUp to CHF 20 cr, in multiple tranches, at 4% all-inclusive interest, 10-year tenor
Consolidated goodwillIn excess of ₹4,000 cr as of 31 March 2026